

Appln. No. 09/744,804  
Amdt. dated November 28, 2003

Amendments to the Specification

Please replace the paragraph beginning on page 6, line 8, with the following amended paragraph:

The chemokine receptor antagonist is preferably selected among truncated RANTES molecules reported in International patent application WO 97/44462, truncated MCP-3, RANTES (missing the first five, six, seven, eight or nine amino acid residues) and MIP-1 $\alpha$  described in International patent application WO 98/06751, truncated RANTES (missing the first two amino acid residues) and MCP-2 described in European patent application No. 97116863.8 or N-terminally extended RANTES (Met-RANTES, Leu-RANTES, and Gln-RANTES) described in WO 96/17935. Met-RANTES is particularly preferred. To the above-cited patent applications, reference is made also for the methods of preparation of the chemokine receptor antagonists mentioned.